Repligen Corp vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
RGEN
Repligen Corp
$182.49 +0.48%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$3.46 +6.62%
Repligen Corp and Recursion Pharmaceuticals, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| RGEN | RXRX | |
|---|---|---|
| Market Cap | $10.25 billion | $1.74 billion |
| Revenue (TTM) | $785.10 million | — |
| Net Income (TTM) | $41.54 million | — |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| RGEN | RXRX | |
|---|---|---|
| P/E Ratio | 249.99 | — |
| Price / Book | 4.85 | — |
| Price / Sales | 13.06 | — |
RGEN and RXRX split the valuation factors evenly.
Profitability
| RGEN | RXRX | |
|---|---|---|
| Net Margin | 5.29% | — |
| Return on Equity | 1.97% | — |
RGEN and RXRX split the profitability factors evenly.
Risk & Sentiment
| RGEN | RXRX | |
|---|---|---|
| Short Interest | 7.13% | 0.29% |
RXRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: RGEN overview, RGEN financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.